Department of Surgery, Rajavithi Hospital, Bangkok 10400, Thailand.
World J Gastroenterol. 2010 Oct 7;16(37):4697-703. doi: 10.3748/wjg.v16.i37.4697.
To determine whether the serum level of matrix metalloproteinase-7 (MMP7) has the potential to diagnosis cholangiocarcinoma from benign biliary tract diseases.
This study was performed according to the PRoBE (a prospective-specimen-collection, retrospective-blinded-evaluation) design. A total of 187 patients with obstructive jaundice were consecutively enrolled. After the diagnostic status of these patients was ascertained, their levels of serum MMP7 were assayed and compared with serum carbohydrate antigen 19-9 (CA19-9). This was conducted in a blinded case (cholangiocarcinoma)-control (benign biliary tract disease) setup.
MMP7 and CA19-9 serum levels were significantly elevated in cholangiocarcinoma patients (P < 0.001). The area under the curve (AUC) from a receiver operating characteristic (ROC) curve analysis for the diagnosis of cholangiocarcinoma, using MMP7 was more accurate than CA19-9 (AUC = 0.84, 95% CI: 0.778-0.903 for MMP7 and AUC = 0.79, 95% CI: 0.708-0.868 for CA19-9). The sensitivity and specificity of serum MMP7 (cut-off value of 5.5 ng/mL) was 75% and 78%, respectively, while the sensitivity and specificity of serum CA19-9 (cut-off value of 100 U/mL) was 68% and 87%, respectively.
Serum values of MMP7 and CA19-9 appear to be useful biomarkers for differentiating cholangiocarcinoma from benign biliary tract obstructive diseases.
确定基质金属蛋白酶-7（MMP7）的血清水平是否有潜力用于从良性胆道疾病中诊断胆管癌。
本研究按照前瞻性标本采集、回顾性盲法评估（PRoBE）设计进行。连续纳入 187 例梗阻性黄疸患者。在确定这些患者的诊断情况后，检测并比较其血清 MMP7 水平与血清糖链抗原 19-9（CA19-9）水平。这是在盲法病例（胆管癌）-对照（良性胆道疾病）设置中进行的。
胆管癌患者的 MMP7 和 CA19-9 血清水平显著升高（P<0.001）。使用 MMP7 进行诊断时，ROC 曲线分析的曲线下面积（AUC）优于 CA19-9（AUC=0.84，95%CI：0.778-0.903 为 MMP7，AUC=0.79，95%CI：0.708-0.868 为 CA19-9）。血清 MMP7（截断值为 5.5ng/mL）的灵敏度和特异性分别为 75%和 78%，而血清 CA19-9（截断值为 100U/mL）的灵敏度和特异性分别为 68%和 87%。
血清 MMP7 和 CA19-9 水平似乎是区分胆管癌与良性胆道梗阻性疾病的有用生物标志物。
